Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 8/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31492336 | 0.92 | GPR119 (0.40) | CHRM2CHRM4CHRM1GPR119CHRM3 | |
| SCHEMBL31492305 | 0.92 | CHRM2 (0.42) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL31492302 | 0.92 | CHRM2 (0.42) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL31492333 | 0.92 | GPR119 (0.40) | CHRM2CHRM4GPR119CHRM3CYP2D6 | |
| SCHEMBL31492294 | 0.92 | CHRM2 (0.42) | CHRM2CHRM4CHRM1GPR119CHRM3 | |
| SCHEMBL31492275 | 0.91 | CHRM4 (0.42) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL31492265 | 0.91 | CHRM4 (0.44) | CHRM4GPR119 | |
| SCHEMBL31492314 | 0.91 | CHRM2 (0.43) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL31492266 | 0.90 | CHRM4 (0.42) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL31492269 | 0.89 | CHRM2 (0.45) | CHRM2CHRM4CHRM1CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092022-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092022-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | CHRM2 2/4885CHRM4 1/4885CHRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.